Is eltrombopag effective in treating aplastic anemia?

Eltrombopag is an oral, small-molecule thrombopoietin receptor agonist. It was originally developed to treat chronic immune thrombocytopenia (ITP) , but in recent years its application in severe aplastic anemia (SAA) has gradually become the focus of clinical attention. The drug stimulates the proliferation and differentiation of megakaryocyte precursor cells in the bone marrow and promotes platelet production, thus improving the problem of peripheral blood cell depletion.

For aplastic anemia, a disease of bone marrow hematopoietic failure, traditional treatments mostly rely on immunosuppressive regimens or hematopoietic stem cell transplantation. However, some patients do not respond well to standard immunosuppressive treatment, or are unable to receive transplantation due to factors such as age and lack of donors. The emergence of eltrombopag has brought new treatment possibilities to this type of "refractory" patients.

Research trends show that while eltrombopag promotes platelet recovery, it may also indirectly promote the production of red blood cells and neutrophils. Some patients showed an increase in peripheral blood cells of all three cell lines after weeks to months of treatment, suggesting that the drug may have broader bone marrow stimulating potential. International guidelines have also gradually incorporated it into first-line or adjuvant treatment recommendations for SAA patients, especially when the initial immunosuppressive response is poor or relapse occurs.

It is worth noting that the efficacy of eltrombopag varies among individuals. Some patients can see significant improvement in blood levels and maintain long-term stability, while other patients may have limited efficacy. Therefore, individualized assessment should be conducted before medication, such as baseline bone marrow status, liver function, etc. At the same time, liver function and blood cell changes need to be closely monitored during treatment to ensure medication safety.

Reference materials:https://go.drugbank.com/drugs/DB06210